A new trading day began on Tuesday, with Fate Therapeutics Inc (NASDAQ: FATE) stock price down -3.20% from the previous day of trading, before settling in for the closing price of $1.25. FATE’s price has ranged from $1.04 to $8.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 77.60%. Meanwhile, its annual earnings per share averaged 0.38%. With a float of $97.88 million, this company’s outstanding shares have now reached $113.88 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is -229.52%, operating margin of -1462.06%, and the pretax margin is -1325.43%.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Fate Therapeutics Inc is 14.06%, while institutional ownership is 87.92%. The most recent insider transaction that took place on Jan 10 ’25, was worth 9,269. In this transaction an insider of this company sold 5,980 shares at a rate of $1.55, taking the stock ownership to the 270,203 shares. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,654 for $1.55, making the entire transaction worth $8,764. This insider now owns 336,707 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 0.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.99% during the next five years compared to -6.65% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Here are Fate Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.67 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Looking closely at Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days average volume was 1.14 million, which is a drop from its year-to-date volume of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 16.07%. Additionally, its Average True Range was 0.12.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 5.38%, which indicates a significant decrease from 12.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.26% in the past 14 days, which was lower than the 95.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7403, while its 200-day Moving Average is $3.0896. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $1.2500. Second resistance stands at $1.2900. The third major resistance level sits at $1.3300. If the price goes on to break the first support level at $1.1700, it is likely to go to the next support level at $1.1300. Now, if the price goes above the second support level, the third support stands at $1.0900.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
With a market capitalization of 137.81 million, the company has a total of 113,894K Shares Outstanding. Currently, annual sales are 63,530 K while annual income is -160,930 K. The company’s previous quarter sales were 3,070 K while its latest quarter income was -47,680 K.
